Astrazeneca Pharma shuts down Bangalore unit

AstraZeneca Pharma India (AZPIL) the subsidiary of British-Swedish multinational pharmaceutical and biologics company AstraZeneca, has shut down its Active Pharmaceutical Ingredient (API) unit in Bengaluru. With this, all API manufacturing activities have been shut down in India.
The reason cited was low demand for a product called Terbutaline Sulphate (TS), which was being exported from this plant. Terbutaline is used to treat asthma, bronchitis and emphysema.

Be the first to comment

Leave a Reply

Your email address will not be published.


*